☆ 4.7 Article

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis

BLOOD (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Pathology

Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation

Camille Laurent et al.

Summary: Despite the effectiveness of CAR-T therapy in B-cell non-Hodgkin lymphomas, durable responses are rare. This study reveals the genetic remodeling and acquired mutations associated with CAR-T resistance, which may lead to dysregulation of B-cell differentiation and tumor aggressiveness.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2022)

添加到收藏夹

Letter Oncology

Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort

Emma Rabinovich et al.

Summary: This study treated 31 diffuse large B-cell lymphoma patients with anti-CD19 CAR T-cell therapy, showing that elevated levels of lactate dehydrogenase are predictive of overall survival. The findings demonstrate the efficacy of CAR T-cell therapy in a diverse urban population and propose novel lactate dehydrogenase cutoffs as prognostic biomarkers.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma

Gloria Iacoboni et al.

Summary: Tisagenlecleucel shows promising efficacy in treating R/R LBCL with a best ORR of 60% and CR of 32%, with a median response duration of 8.9 months. Treatment with tisa-cel in a European SOC setting demonstrates a manageable safety profile and durable complete responses for patients with LBCL.

CANCER MEDICINE (2021)

添加到收藏夹

Article Hematology

Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy

Gloria Iacoboni et al.

Summary: CAR-T cell therapy provides long-term remissions for patients with relapsed or refractory large B-cell lymphoma. Total metabolic tumor volume (TMTV) and maximum standardized uptake value (SUVmax) measured by 18FDG-PET can predict efficacy, with high baseline TMTV associated with shorter PFS and potential impact on OS. SUVmax at baseline did not significantly affect outcomes. This therapy is most beneficial for patients with higher metabolic tumor burden.

ANNALS OF HEMATOLOGY (2021)

添加到收藏夹

Review Oncology

Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell Killing

Jean Lemoine et al.

Summary: CAR T-cell therapy has emerged as a promising treatment for cancers, but a significant proportion of patients develop resistance to the treatment. Studies suggest that activation of apoptosis through death receptor signaling is a major mechanism of CAR T-cell cytotoxicity in vivo.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Bispecific antibodies for the treatment of lymphomas: Promises and challenges

Stephen J. Schuster

Summary: Bispecific antibodies can redirect T cell-mediated cytotoxicity towards tumor cells by combining T-cell receptor-specific monoclonal antibodies with tumor-targeting antibodies, thereby focusing cytotoxic effects on tumor cells independently of T-cell receptor specificity. Early results from phase 1 clinical trials targeting CD20 on B cells and engaging T cells via CD3 have shown promising potential for treating relapsed or refractory B-cell lymphomas.

HEMATOLOGICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy

Nicholas B. Figura et al.

Summary: Most patients who recur after CAR T therapy experience a component of local progression. Lesions with high-risk features, particularly large size, are associated with inferior treatment efficacy and patient survival. Locally directed therapies to high-risk lesions, such as radiation therapy, may be a viable strategy to prevent CAR T failures in select patients.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

添加到收藏夹

Letter Oncology

Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy

Chunmeng Wang et al.

Summary: PD-1 blockade therapy may be effective as salvage therapy for patients with relapsed/refractory DLBCL after failure of CART19/20 therapy, helping to alleviate the disease and produce longer efficacy. In this study, some patients achieved complete remissions after anti-PD-1 therapy, while others experienced disease progression.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Loretta J. Nastoupil et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Jeremy S. Abramson et al.

LANCET (2020)

添加到收藏夹

Article Hematology

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

Laetitia Vercellino et al.

BLOOD ADVANCES (2020)

添加到收藏夹

Article Hematology

Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

Marcelo C. Pasquini et al.

BLOOD ADVANCES (2020)

添加到收藏夹

Article Hematology

Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL

Rakesh Awasthi et al.

BLOOD ADVANCES (2020)

添加到收藏夹

Letter Hematology

Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy

Victor A. Chow et al.

AMERICAN JOURNAL OF HEMATOLOGY (2019)

添加到收藏夹

Letter Hematology

Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss

Ali Bukhari et al.

AMERICAN JOURNAL OF HEMATOLOGY (2019)

添加到收藏夹

Article

Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy

Michael Byrne et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

添加到收藏夹

Article Oncology

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

Frederick L. Locke et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Oncology

Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells

Pavel Otahal et al.

ONCOIMMUNOLOGY (2016)

添加到收藏夹

Article Oncology

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

Bruce D. Cheson et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.